1 domain / 2 areas / 1 specialization
Xpira Pharmaceuticals
Data updated
Xpira Pharmaceuticals is a Toronto-based private biotech developing psilocybin-assisted therapy for anorexia nervosa (AN), a condition with no currently approved pharmacological or psychotherapeutic treatments. Founded in 2020 by leaders from the Canadian and Dutch pharmaceutical industries, the company received FDA IND approval in September 2022 for a Phase 2a clinical trial. Xpira is a portfolio company of Origin Therapeutics Holdings. Dr. Allan Kaplan of CAMH and the University of Toronto serves as VP of Clinical Development.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Phase II
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Jun 17, 2024 - clinical-trial-registry - ClinicalTrials.gov - Psilocybin (25mg oral) / Psilocybin Phase 2a Programme (Anorexia Nervosa) — LIKELY STALLED
Next known catalyst
No next milestone forecast yet.
Development Programmes
1Psilocybin (25mg oral)
PsilocybinAnorexia nervosa
Programme Tracker
Eating Disorders
No public updates since 2022 IND clearance; trial (NCT04505189) originally estimated completion June 2024; parent company Origin Therapeutics merged into Safe Supply Streaming Co.
Milestones
ind-filed
CompletedActual: Sep 1, 2022
FDA IND approval received for psilocybin in anorexia nervosa — randomized, quadruple-masked, parallel-group trial (25mg vs 1mg active placebo, target n=60 across 6 sites in US/Ireland/UK)
Why it matters: One of the first FDA INDs for psilocybin in anorexia nervosa. AN has the highest mortality of any psychiatric disorder with very few effective treatments. The 6-site international design was ambitious for a small biotech.
Company milestone
CompletedActual: Sep 1, 2023
Parent company Origin Therapeutics merged with Safe Supply Streaming Co. on CSE
Why it matters: Corporate restructuring of the parent company may have diverted resources and attention from the Xpira trial. Safe Supply Streaming operates in a completely different space (safe drug supply).
Company milestone
CompletedActual: Jun 1, 2024
Original trial completion date passed (June 2024) with no enrollment updates, data readouts, or press releases since 2022
Why it matters: Over 3 years of silence after IND clearance is a strong signal the trial has stalled. No enrollment milestones were ever publicly announced. The programme may be dormant pending corporate strategy decisions or new funding.
Recorded Events
Jun 1, 2024: Company milestone
Sep 1, 2023: Company milestone
Sep 1, 2022: ind-filed
Quick Facts
- Type
- Private Biotech
- Founded
- 2020
- Lead Stage
- Phase II
- Website
- Visit